Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody

Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical firm specializing in innovative inhaled therapies for serious pulmonary and central nervous system disorders, has announced that the U.S. Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for PUR3100 and issued a study may proceed letter.

Brain diagnostics innovator BrainScope has secured new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) as part of its ongoing Series B equity financing round. This investment will support the development of an Artificial Intelligence / Machine Learning-derived brain-activity-based biomarker aimed at predicting the future onset of Alzheimer’s disease.

Unravel Biosciences, Inc. (referred to as "Unravel") has unveiled a pioneering initiative known as rareSHIFT™, aimed at expediting patient-centric drug discovery and translation with unmatched speed.

ST Pharm recently celebrated the completion of its groundbreaking ceremony, marking a significant stride in its efforts to expand its oligonucleotide manufacturing capacity and capabilities.

Following FDA authorization and CDC recommendation, Rite Aid (NYSE: RAD) has announced that eligible customers can now schedule appointments to receive the updated COVID-19 (2023-2024) vaccines at its locations and Bartell Drugs locations in the Pacific Northwest. Appointments are available starting on Friday, September 22.

Daiichi Sankyo (TSE: 4568) has announced that quizartinib has received a favorable recommendation for approval in the European Union (EU). This approval is for its use in combination with standard cytarabine and anthracycline induction, as well as standard cytarabine consolidation chemotherapy.

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF), a North American biopharmaceutical company dedicated to the development of patient-centric medications for orphan and rare diseases, has announced a significant update.

Acticor Biotech (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for treating cardiovascular emergencies, has announced its refined development plan for Acute Ischemic Stroke (AIS) aimed at obtaining glenzocimab's registration in Europe and the United States.

Biosyngen Pte Ltd (referred to as "Biosyngen") has announced that the U.S. FDA has granted clearance for the Investigational New Drug (IND) application for the Phase I/II clinical trial of BRL03.